Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence
Patent
1997-04-30
1999-10-05
Tsang, Cecilia J.
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
25 or more amino acid residues in defined sequence
530325, 530326, 530327, 530328, 530329, 530330, 514 12, 514 13, 514 14, 514 15, 514 16, 514 17, 514 18, 514885, C07K 700
Patent
active
059626348
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to biologically active compounds which are similar to regions of the high affinity Fc receptor for immunoglobulin E.
BACKGROUND OF THE INVENTION
Clinical bone marrow transplantation is an important therapeutic treatment for several diseases including high risk leukemia, aplastic anemia, and severe combined immunodeficiency. In addition, there is a wide range of metabolic and genetic disorders that can potentially be corrected by this approach. However, the usefulness of marrow transplantation is currently limited by several important risk factors, the principal one being graft-versus-host disease (GVHD), an often times lethal complication which occurs in a high proportion of transplants.
The risk of GVHD can be reduced by HLA matching of the marrow donor and recipient, with a matched sibling being the primary choice. Yet, less than 30% of the patients in North America have an HLA-matched sibling, and therefore must seek suitable unrelated HLA-matched donors from the National Marrow Donor Program. The probability of finding an unrelated HLA-matched donor is currently on the order of 30-40% and depend on the total number of donors registered. In both related and unrelated HLA-matched transplant situations, the risk of GVHD is still quite high due to disparity of non-HLA multiple minor histocompatibility (H) antigens. GVHD is somewhat higher in unrelated cases, as this increases the probability of differences at these loci.
Mature donor T cells contaminating the marrow inoculum are responsible for GVHD. Several studies have shown that depletion of these T cells significantly diminishes the incidence of disease. However, the elimination of donor T cells has also resulted in a greater incidence of leukemic relapse. It seems important to provide at least some level of T cell immunocompetency in these completely immunocompromised patients to not only combat residual leukemia cells but also to counter opportunistic infections. In this respect, the same GVHD-reactive donor T cells may be important for targeting leukemia cells expressing the same host allogeneic histocompatibility antigens. Therapeutic approaches that could ameliorate the pathogenic tissue destruction accompanying GVHD, particularly in the gut and skin, but that would allow for continued anti-leukemia activity would greatly benefit marrow transplant patients.
Immediate allergic responses, also referred to as type 1 hypersensitivity reactions, are mediated through the interaction of immunoglobulin E (IgE) with the .alpha.-chain of its high affinity Fc receptor, Fc.epsilon.R1. The binding of a multivalent allergen to an IgE-Fc.epsilon.R1complex initiates a cross-linking of the receptor and consequent cellular activation. These high affinity receptors are found primarily on mast cells and basophils. When activated by an allergen, these cells respond by releasing histamine, eicosanoids and cytokines.
In addition to its high affinity Fc receptor, IgE binds to a low affinity receptor, the Fc.epsilon.R2, which is found on B cells, T cells, macrophages, NK cells, eosinophils, platelets, follicular dendritic cells as well as several other cell types. Activation of the Fc.epsilon.R2 has been implicated in IgE-dependent cell cytotoxicity (ADCC) as well as in allergic inflammation.
Many different fine mapping studies have been conducted on the binding of the IgE to its Fc receptors. The consensus mapping data is confirmed by a recent study by Nissim et al. (1993) J. Immunol. 150: 1365-1374, which is incorporated herein by reference, showing that the binding activity for both the high and low affinity receptors resides within the C.epsilon.3 (the third constant domain) of the IgE. Data show that the species specific binding of IgE to the Fc.epsilon.R1 is contained within the first 16 amino acids of the CE3, whereas no species specific binding is observed in the same region with respect to binding the Fc.epsilon.R2.
There is a need for compounds and methods which can inhibit IgE-Fc.epsilon.R1 interaction. I
REFERENCES:
patent: 5292867 (1994-03-01), Chang
HCAPLUS DN 118:192247, Ball et al., Int. S. Pept. Protein Res., 40(5), 370-9, 1992.
Claman et al., "Immunoglobulin Dysregulation in Murine Graft-vs-Host Disease: A Hyper-IgE Syndrome", Clin. Imm. Immunopath., 1990, 56, 46-53.
Korngold et al., "Variable Capacity of L3T4.sup.30 T Cells to Cause Lethal Graft-Versus-Host Disease Across Minor Histocompatibility Barriers in Mice", J. Exp. Med., 1987, 165, 1552-1564.
Merrifield, "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide", J. Am. Chem. Soc., 1963, 15, 2149-2154.
Beavil et al., "Structural Basis of the IgE-Fc.di-elect cons.RI Interaction", Biochem. Soc. Trans., 1993, 21, 968-972.
Murphy et al., "Role of Mast Cells in Early Epithelial Target Cell Injury in Experimental Acute Graft-Versus-Host Disease", J. Invest. Derma., 1994, 102, 451-461.
Nissim et al., "Fine Specificity of the IgE Interaction with the Low and High Affinity Fc Receptor", J. Immunol., 1993, 150, 1365-1374.
Wang et al., "Epidermal Langherhans Cells from Normal Human Skin Bind Monomeric IgE via Fc.di-elect cons.RI", J. Exp. Med., 1992, 175, 1353-1365.
HCAPLUS DN: 118:122551, McDunnell et al., J. of Immunol., 149(5), 1626-30, 1992.
HCAPLUS DN 116:35978, Miller et al., Arch. Biochem. Biophys., 291(1). 69-75, 1991.
HCAPLUS DN 115:156552, Childerstone et al., J. Immunol., 146(5), 1463-9, 1991.
HCAPLUS DN 111:149428. Thompson et al., J. Biol. Chem., 264(19), 11511-20, 1989.
Beavil Andrew J.
Gould Hannah J.
Jameson Bradford A.
Korngold Robert
McDonnell James M.
Delacroix-Muirheid C.
King's College
Thomas Jefferson University
Tsang Cecilia J.
LandOfFree
IgE antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IgE antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IgE antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1172904